94.84
price up icon0.27%   0.24
 
loading
Schlusskurs vom Vortag:
$94.60
Offen:
$94.62
24-Stunden-Volumen:
979.53K
Relative Volume:
0.48
Marktkapitalisierung:
$7.17B
Einnahmen:
$35.93M
Nettoeinkommen (Verlust:
$-244.56M
KGV:
-24.01
EPS:
-3.95
Netto-Cashflow:
$-157.31M
1W Leistung:
+0.27%
1M Leistung:
+37.69%
6M Leistung:
+109.48%
1J Leistung:
+79.58%
1-Tages-Spanne:
Value
$94.58
$94.88
1-Wochen-Bereich:
Value
$94.38
$95.06
52-Wochen-Spanne:
Value
$33.19
$95.06

Merus N V Stock (MRUS) Company Profile

Name
Firmenname
Merus N V
Name
Telefon
31 030 253 8800
Name
Adresse
YALELAAN 62, 3584 CM UTRECHT
Name
Mitarbeiter
260
Name
Twitter
@MerusNV
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
MRUS's Discussions on Twitter

Vergleichen Sie MRUS mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MRUS
Merus N V
94.84 7.17B 35.93M -244.56M -157.31M -3.95
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
420.99 107.73B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
642.74 62.04B 14.21B 4.46B 3.56B 39.69
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
483.43 62.73B 2.46B -319.09M -52.09M -2.4669
Biotechnology icon
ARGX
Argen X Se Adr
831.85 51.09B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
166.16 34.67B 398.11M -1.03B -868.57M -5.7032

Merus N V Stock (MRUS) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-09-17 Eingeleitet Barclays Overweight
2025-08-25 Eingeleitet Alliance Global Partners Buy
2025-02-13 Eingeleitet Piper Sandler Overweight
2025-02-07 Eingeleitet Wells Fargo Overweight
2024-11-21 Eingeleitet Goldman Buy
2024-10-24 Eingeleitet UBS Buy
2024-03-28 Eingeleitet Truist Buy
2024-03-04 Bestätigt Needham Buy
2023-11-02 Eingeleitet Canaccord Genuity Buy
2023-08-21 Eingeleitet TD Cowen Outperform
2022-08-02 Eingeleitet Stifel Buy
2022-02-11 Eingeleitet BMO Capital Markets Outperform
2022-02-10 Eingeleitet Needham Buy
2021-11-17 Fortgesetzt Guggenheim Buy
2021-06-07 Hochstufung Citigroup Neutral → Buy
2021-04-08 Eingeleitet William Blair Outperform
2021-03-16 Eingeleitet SVB Leerink Outperform
2020-06-26 Eingeleitet H.C. Wainwright Buy
2020-05-27 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2019-11-20 Fortgesetzt Guggenheim Buy
2019-06-28 Eingeleitet ROTH Capital Buy
2019-04-12 Fortgesetzt Guggenheim Buy
2019-04-03 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2019-03-27 Eingeleitet Berenberg Buy
2018-01-02 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-03-21 Herabstufung Citigroup Buy → Neutral
2016-12-22 Hochstufung Citigroup Neutral → Buy
2016-11-07 Herabstufung Citigroup Buy → Neutral
2016-06-13 Eingeleitet Citigroup Buy
2016-06-13 Eingeleitet Guggenheim Buy
2016-06-13 Eingeleitet Wedbush Outperform
Alle ansehen

Merus N V Aktie (MRUS) Neueste Nachrichten

pulisher
04:15 AM

Will Merus N.V. stock sustain high P E ratios2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - newser.com

04:15 AM
pulisher
03:56 AM

What risks investors should watch in Merus N.V. stockWeekly Stock Recap & Daily Profit Maximizing Tips - newser.com

03:56 AM
pulisher
03:16 AM

Can Merus N.V. stock double in next 5 yearsJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com

03:16 AM
pulisher
03:04 AM

What market sentiment indicators show for Merus N.V. (2GH) stock2025 Market Overview & Real-Time Volume Analysis - newser.com

03:04 AM
pulisher
02:41 AM

Is Merus N.V. stock a buy before product launches2025 Fundamental Recap & AI Powered Trade Plan Recommendations - newser.com

02:41 AM
pulisher
02:18 AM

Why Merus N.V. stock remains on buy listsJuly 2025 Retail & Reliable Price Breakout Alerts - newser.com

02:18 AM
pulisher
02:15 AM

Is Merus N.V. stock resilient to inflationJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - newser.com

02:15 AM
pulisher
01:28 AM

Market reaction to Merus N.V.’s recent newsWeekly Market Outlook & Stock Portfolio Risk Control - newser.com

01:28 AM
pulisher
12:40 PM

Can Merus N.V. (2GH) stock sustain revenue momentumDay Trade & AI Enhanced Execution Alerts - newser.com

12:40 PM
pulisher
Oct 27, 2025

Key metrics from Merus N.V.’s quarterly dataMarket Performance Report & High Accuracy Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Why Merus N.V. (2GH) stock could outperform next yearTrade Analysis Report & Short-Term Trading Opportunity Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Why Merus N.V. stock appeals to dividend seekers2025 Price Targets & Capital Protection Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Merus N.V.’s Zenocutuzumab Study Termination: Market Implications - TipRanks

Oct 27, 2025
pulisher
Oct 27, 2025

Will Merus N.V. stock deliver better than expected guidanceWeekly Stock Report & Technical Confirmation Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

Is Merus N.V. stock attractive for income investorsEarnings Performance Report & Fast Entry Momentum Trade Alerts - newser.com

Oct 27, 2025
pulisher
Oct 27, 2025

How big funds are accumulating Merus N.V. (2GH) stock2025 Valuation Update & Long-Term Growth Stock Strategies - newser.com

Oct 27, 2025

Finanzdaten der Merus N V-Aktie (MRUS)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Merus N V-Aktie (MRUS) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Silverman Peter B.
COO & GC
Jul 17 '25
Sale
60.00
25,000
1,500,000
0
$36.44
price down icon 2.31%
$89.95
price down icon 3.43%
$29.16
price up icon 0.41%
$106.58
price up icon 0.51%
biotechnology ONC
$318.00
price up icon 0.81%
$166.16
price up icon 1.32%
Kapitalisierung:     |  Volumen (24h):